FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: Ongoing phase 2 trials in patients with CIDP with batoclimab (NCT05581199) and nipocalimab (NCT05327114)—agents targeting the FcRn system—will explore the value of this therapeutic approach.